iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.13, Zacks reports.
iTeos Therapeutics Stock Down 0.6 %
Shares of iTeos Therapeutics stock traded down $0.04 during trading on Friday, reaching $7.05. The company's stock had a trading volume of 287,485 shares, compared to its average volume of 450,545. iTeos Therapeutics has a 12-month low of $6.67 and a 12-month high of $18.75. The company has a market capitalization of $257.56 million, a P/E ratio of -2.24 and a beta of 1.38. The business has a 50 day moving average price of $7.52 and a 200-day moving average price of $9.42.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. Wedbush restated an "outperform" rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday. HC Wainwright restated a "buy" rating and set a $46.00 target price on shares of iTeos Therapeutics in a report on Thursday. Wells Fargo & Company cut their target price on iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, JPMorgan Chase & Co. cut their price target on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research report on Thursday.
Read Our Latest Stock Report on ITOS
iTeos Therapeutics Company Profile
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Read More
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
